Every material Form 8-K ArriVent BioPharma, Inc. has filed with the SEC since October 13, 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
ArriVent reported third-quarter 2026 results with a net loss of $40.3 million, up from $35.0 million a year earlier, as research and development and general and administrative expenses rose. The company also said its Phase 3 FURVENT trial of firmonertinib did not meet its primary endpoint of progression-free survival, and that Stuart Lutzker, its President of Research and Development and a director, will retire effective December 1, 2026. For shareholders, the trial miss is the central development, with the wider loss and leadership change adding to the negative picture.
FURVENT missed its primary endpoint of progression-free survival by blinded independent central review; median PFS was 11.0 months at 240 mg versus 9.5 months with chemotherapy (HR 0.75; p=0.0654).
Q3 2026 net loss was $40.3 million versus $35.0 million in Q3 2025; collaboration revenue was $5.0 million versus none a year earlier.
Net loss per share was $0.81 versus $0.83 a year earlier; cash and investments were $393.2 million at September 30, 2026, expected to fund operations to mid-2028.
Dr. Stuart Lutzker retires effective December 1, 2026, with a one-time payment of $428,438.21 under a planned retirement agreement; Chief Medical Officer Priti Patel, M.D., will lead R&D from that date.
ArriVent BioPharma reported initial Phase 1 data for its cadherin-17-targeted antibody-drug conjugate ARR-217 at the ESMO Congress 2026, based on 123 patients treated as of an August 5, 2026 data cutoff. The company said the drug was generally well tolerated and has advanced ARR-217 into a Phase 1b dose optimization study, with further data expected in 2027. The results are early and come from an open-label study, and the filing reports a notable rate of Grade 3 or higher treatment-related adverse events.
At the 6 mg/kg Q3W dose, the objective response rate was 44.8% (13/29) and the disease control rate was 93.1% (27/29) in pre-treated colorectal cancer patients.
Across all doses, 30.1% (37/123) of patients had Grade 3 or higher treatment-related adverse events, including neutropenia (12.2%) and diarrhea (8.9%).
ARR-217 has advanced into Phase 1b dose optimization at 5 and 6 mg/kg Q3W, with further dose optimization data expected in 2027.
ArriVent will host a virtual webinar on Monday, October 26, 2026, at 8 am ET.
ArriVent BioPharma announced the publication of Phase 1b FURTHER trial results for its drug firmonertinib in the journal Cancer Cell, covering patients with EGFR PACC-mutant non-small cell lung cancer. The filing is a clinical data and publication update with no financial results, guidance, or financing terms, so its direct effect on shareholders is not quantified in the filing.
Reported confirmed overall response rates of 43% (160 mg) and 68% (240 mg) in front-line EGFR PACC-mutant NSCLC, per blinded independent central review.
Reported 11.1- and 16.0-month median progression-free survival at the two doses.
The company continues to enroll patients in its global Phase 3 ALPACCA trial.
ArriVent BioPharma announced on October 12, 2026 that it dosed the first U.S. patient in a Phase 1 trial of ARR-002, a MUC16/NaPi2b dual-target antibody-drug conjugate for ovarian and endometrial cancer. The filing reports no financial results, guidance, or cost figures, so the update is a clinical development milestone for the company's pipeline.
First U.S. patient dosed in the Phase 1 trial of ARR-002 (NCT07755436), announced October 12, 2026
ARR-002 is described as the company's second ADC to enter the clinic
In August 2026, ArriVent licensed ARR-002 to Shanghai Allist Pharmaceuticals for Greater China, with other rights retained by ArriVent
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every ArriVent BioPharma, Inc. filing is on SEC EDGAR ↗. 8-K briefs of other companies →